%0 Journal Article
%T Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement.
%A Fargnoli MC
%A Bardazzi F
%A Bianchi L
%A Dapavo P
%A Fabbrocini G
%A Gisondi P
%A Micali G
%A Offidani AM
%A Pellacani G
%A Skroza N
%A Angileri RG
%A Burlando M
%A Campanati A
%A Carrera CG
%A Chiricozzi A
%A Conti A
%A Simone C
%A Di Lernia V
%A Errichetti E
%A Galluzzo M
%A Guarneri C
%A Lasagni C
%A Lembo S
%A Loconsole F
%A Megna M
%A Musumeci ML
%A Prignano F
%A Richetta AG
%A Trovato E
%A Venturini M
%A Peris K
%A Pinton PC
%J J Clin Med
%V 12
%N 10
%D 2023 May 18
%M 37240650
%F 4.964
%R 10.3390/jcm12103545
%X Brodalumab is a recombinant, fully human immunoglobulin IgG2 monoclonal antibody specifically targeted against interleukin-17RA that has been approved for the treatment of moderate-to-severe psoriasis in Europe. We developed a Delphi consensus document focused on brodalumab for the treatment of moderate-to-severe psoriasis. Based on published literature and their clinical experience a steering committee drafted 17 statements covering 7 domains specific to the treatment of moderate-to-severe psoriasis with brodalumab. A panel of 32 Italian dermatologists indicated their level of agreement using a 5-point Likert scale (from 1 = "strongly disagree" to 5 = "strongly agree") using an online modified Delphi method. After the first round of voting (32 participants), positive consensus was reached for 15/17 (88.2%) of the proposed statements. Following a face-to-face virtual meeting, the steering committee decided that 5 statements would form "main principles" and 10 statements formed the final list. After a second round of voting, consensus was reached in 4/5 (80%) of the main principles and 8/10 (80%) for consensus statements. The final list of 5 main principles and 10 consensus statements identify key indications specific to the use of brodalumab in the treatment of moderate-to-severe psoriasis in Italy. These statements aid dermatologists in the management of patients with moderate-to-severe psoriasis.